Clinical Trials Browser

Phase 1/2 × Her2 Positive Metastatic Breast Cancer × Clear all

NCT01495884 2015-10-26

The Myocet/Lapatinib Study. ICORG 10-03, V5

Phase 1/2 Terminated

Her2 Positive Metastatic Breast Cancer